Multidisciplinary task force releases consensus document on biosimilars

October 2, 2017
While several national and international medical subspecialty organizations have demonstrated conflicting views on the use of biosimilars for…

WHO creates pilot program to use biosimilars to address ‘prohibitively expensive’ cancer drugs

September 28, 2017
The WHO has launched a pilot project to encourage the development of biosimilar versions of rituximab and trastuzumab – two products on the WHO…

Amgen to collaborate with Simcere to co-develop, commercialize biosimilars in China

September 27, 2017
Amgen and Simcere Pharmaceutical Group announced a collaboration to co-develop and commercialize four biosimilars in China. The deal includes…

Expert panel discusses concerns, opportunities surrounding biosimilars in the US

September 27, 2017
Biosimilars remain an unfamiliar and oftentimes controversial topic among physicians in the U.S. Unanswered questions surrounding both the scientific…

Pfizer files suit claiming Johnson & Johnson stifles biosimilar competition

September 21, 2017
Pfizer, the manufacturer of Inflectra, a biosimilar to Janssen’s Remicade, filed a lawsuit against Johnson & Johnson, the parent company of…

Samsung Bioepis receives positive opinion for Herceptin biosimilar

September 18, 2017
Samsung Bioepis received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Ontruzant
FDA NewsPerspective

FDA approves Mvasi, first biosimilar for cancer

September 14, 2017
The FDA today approved the first biosimilar for cancer — bevacizumab-awwb — to treat patients with multiple types of cancer…

ACR applauds FDA Reauthorization Act of 2017, initiatives to quicken biosimilar approvals

August 28, 2017
In a statement from Sharad Lakhanpal, MBBS, MD, president of the American College of Rheumatology, the group applauded the enactment of the FDA…
FDA News

FDA approves Humira biosimilar Cyltezo

August 28, 2017
The FDA has approved the second biosimilar to Humira, Cyltezo, for several gastroenterological, rheumatological and dermatological indications…
In the JournalsPerspective

Biosimilar demonstrates similar safety, efficacy as rituximab for follicular lymphoma

August 7, 2017
Rituximab biosimilar GP2013 demonstrated similar safety and efficacy as its reference agent in patients with previously untreated, advanced…